Cover Image
市場調查報告書

化療誘發性末梢神經病變:全球臨床實驗趨勢

Chemotherapy Induced Peripheral Neuropathy Global Clinical Trials Review, H1, 2016

出版商 GlobalData 商品編碼 298066
出版日期 內容資訊 英文 81 Pages
訂單完成後即時交付
價格
Back to Top
化療誘發性末梢神經病變:全球臨床實驗趨勢 Chemotherapy Induced Peripheral Neuropathy Global Clinical Trials Review, H1, 2016
出版日期: 2016年06月15日 內容資訊: 英文 81 Pages
簡介

本報告提供全球化療誘發性末梢神經病變治療藥臨床實驗趨勢之相關調查,提供您已開發國家及新興國家市場上臨床實驗數量,各階段及進展狀況臨床實驗數量,治療藥臨床實驗主要的參與企業,有潛力的藥劑等資訊。

本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區主要5國的臨床實驗數量
    • 歐洲主要5國的臨床實驗數量
    • 北美主要國家的臨床實驗數量
    • 中東·非洲主要國家的臨床實驗數量
    • 中南美主要5國的臨床實驗數量

G7各國臨床實驗數量:癌症治療藥臨床實驗上化療誘發性末梢神經病變的比例

G7各國的各階段臨床實驗數量

G7各國臨床實驗數量:各進展狀況

E7各國臨床實驗數量:癌症治療藥臨床實驗上化療誘發性末梢神經病變的比例

E7各國的各階段臨床實驗數量

E7各國臨床實驗數量:各進展狀況

各階段臨床實驗數量

  • 進行中的臨床實驗:各階段

各進展狀況臨床實驗數量

臨床實驗的目標達成情形

一定期間所採用的實驗對像

贊助商類別的臨床實驗數量

有潛力的贊助商

化療誘發性末梢神經病變治療藥臨床實驗主要的參與企業

有潛力的藥劑

臨床實驗簡介概要

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC3479CTIDB

GlobalData's clinical trial report, "Chemotherapy Induced Peripheral Neuropathy Global Clinical Trials Review, H1, 2016" provides an overview of Chemotherapy Induced Peripheral Neuropathy clinical trials scenario. This report provides top line data relating to the clinical trials on Chemotherapy Induced Peripheral Neuropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Chemotherapy Induced Peripheral Neuropathy to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Chemotherapy Induced Peripheral Neuropathy to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Chemotherapy Induced Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Region, 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, North America, Top Countries, 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016*
  • Proportion of Chemotherapy Induced Peripheral Neuropathy to Oncology Clinical Trials, G7 Countries (%), 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Chemotherapy Induced Peripheral Neuropathy to Oncology Clinical Trials, E7 Countries (%), 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Phase, 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

  • Chemotherapy Induced Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Region (%), 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016*
  • Proportion of Chemotherapy Induced Peripheral Neuropathy to Oncology Clinical Trials, G7 Countries (%), 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Chemotherapy Induced Peripheral Neuropathy to Oncology Clinical Trials, E7 Countries (%), 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • GlobalData Methodology
Back to Top